rs78657866
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PS2PM3PP3PM2_SupportingPS3_ModeratePP4_Moderate
This summary comes from the ClinGen Evidence Repository: The c.2944G>A (p.Val982Met) missense variant has been reported in at least three compound heterozygous probands with a phenotype highly specific to GT (PMID:28983057, 25539746,15099289); one of which was a de novo occurrence (PMID:25539746). It is found at an extremely low frequency (MAF of 0.00006486 in the non-Finnish European population from gnomAD). This variant is predicted by HSF and MaxEntScan to result in a broken splice donor site. Flow cytometry found that this variant had a marked deleterious effect on αIIbβ3 expression (~25% of control levels) in COS-7 cells (PMID:15099289). In summary, this variant meets criteria to be classified as Pathogenic for GT. GT-specific criteria applied: PS2, PM3, PM2_supporting, PS3_Moderate, PP3, and PP4_moderate. LINK:https://erepo.genome.network/evrepo/ui/classification/CA16608466/MONDO:0010119/011
Frequency
Consequence
NM_000419.5 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ITGA2B | NM_000419.5 | c.2944G>A | p.Val982Met | missense_variant, splice_region_variant | 29/30 | ENST00000262407.6 | NP_000410.2 | |
ITGA2B | XM_011524749.2 | c.2995G>A | p.Val999Met | missense_variant, splice_region_variant | 28/29 | XP_011523051.2 | ||
ITGA2B | XM_011524750.2 | c.3096+189G>A | intron_variant | XP_011523052.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ITGA2B | ENST00000262407.6 | c.2944G>A | p.Val982Met | missense_variant, splice_region_variant | 29/30 | 1 | NM_000419.5 | ENSP00000262407.5 | ||
ITGA2B | ENST00000648408.1 | c.2373+189G>A | intron_variant | ENSP00000498119.1 | ||||||
ITGA2B | ENST00000587295.5 | c.252+1363G>A | intron_variant | 3 | ENSP00000467269.1 | |||||
ITGA2B | ENST00000592462.5 | n.2643G>A | non_coding_transcript_exon_variant | 15/15 | 5 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152178Hom.: 0 Cov.: 32
GnomAD4 exome AF: 0.00000342 AC: 5AN: 1461518Hom.: 0 Cov.: 31 AF XY: 0.00000413 AC XY: 3AN XY: 727102
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152178Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74344
ClinVar
Submissions by phenotype
Glanzmann thrombasthenia Pathogenic:1
Pathogenic, reviewed by expert panel | curation | ClinGen Platelet Disorders Variant Curation Expert Panel, ClinGen | Sep 06, 2020 | The c.2944G>A (p.Val982Met) missense variant has been reported in at least three compound heterozygous probands with a phenotype highly specific to GT (PMID: 28983057, 25539746,15099289); one of which was a de novo occurrence (PMID: 25539746). It is found at an extremely low frequency (MAF of 0.00006486 in the non-Finnish European population from gnomAD). This variant is predicted by HSF and MaxEntScan to result in a broken splice donor site. Flow cytometry found that this variant had a marked deleterious effect on αIIbβ3 expression (~25% of control levels) in COS-7 cells (PMID: 15099289). In summary, this variant meets criteria to be classified as Pathogenic for GT. GT-specific criteria applied: PS2, PM3, PM2_supporting, PS3_Moderate, PP3, and PP4_moderate. - |
not provided Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Sep 27, 2016 | The V982M variant in the ITGA2B gene has been reported previously (as V951M due to the use of alternate nomenclature) in assocation with Glanzmann thrombasthenia (Nurden et al., 2004; Jallu et al., 2010). In one individual, V982M was identified in the compound heterozygous state with a splice site variant (Nurden et al., 2004), while in another individual, no second pathogenic variant was identified (Jallu et al., 2010). The V982M variant was not observed in approximately 6500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The V982M variant is a conservative amino acid substitution, which occurs at a position that is conserved in mammals. Functional studies demonstrate that V982M results in significant loss of ITGA2b protein surface expression (Nurden et al., 2004). The V982M variant is a strong candidate for a pathogenic variant, however the possibility it may be a rare benign variant cannot be excluded. - |
Glanzmann thrombasthenia 1 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | ISTH-SSC Genomics in Thrombosis and Hemostasis, KU Leuven, Center for Molecular and Vascular Biology | - | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at